SESSION TITLE: Interstitial Lung Disease Posters II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a chronic and fibrosing disease characterized by a progressive loss of lung function and poor prognosis. The pathogenesis of the IPF is complex and the mechanisms involved are still unknown. Histidine-rich glicoprotein (HRG) is a plasma protein that interacts with many ligands and regulates a number of important biological processes. HRG is constitutively present at high concentrations in plasma. Previous studies have shown that HRG is able to modulate the activation of the fibroblast growth factor receptor. The aim of this study was to determine whether the levels of HRG in plasma of IPF patients were predictive of lung function.
METHODS: We collected plasma samples from 14 IPF patients (12/2: males/female); with an average age of 62.5 ± 2.0 years; 9 ex-smokers, 1 current-smoker and 4 non-smokers. Eleven of them showed typical topographic images (HRTC) of IPF, and the others presented a suggestive pattern. We confirmed diagnosis by lung biopsy in 3 patients. As the control group we used plasma from 10 healthy non-smoking subjects. Plasma levels of HRG were measured by ELISA. Data were analyzed with Mann-Whitney test and linear regression analyses.
RESULTS: We observed a significant decrease of HRG plasma levels in IPF patients compared with the control group (81.9 ± 5.3 μg/ml vs 103.8 ± 4.1 μg/ml; p<0.001). We found a positive and significant relationship between HRG plasma levels and both DLCO (percentage of predicted value) and 6 minutes walking test (meters walked) (Spearman r = 0.39; p<0.05, and r = 0.61; p<0.001, respectively). We also found a positive relationship between the decreased levels of HRG in plasma and pack/years smoked (r = 0.66; p<0.001).
CONCLUSIONS: Our results illustrate that a decreased plasmatic levels of HRG is associated to the progression of illness in IPF patients.
CLINICAL IMPLICATIONS: Our data suggest that HRG could be used as a biomarker to evaluate the evolution and prognosis of IPF patients, supporting the need for a larger study.
DISCLOSURE: The following authors have nothing to disclose: Glenda Ernst, Ezequiel Dantas, Fabian Caro, Santiago Rossi, Antonella Merlotti, Augusto Varesse, Gabriel Duette, Jorge Geffner, Pedro Grynblat
No Product/Research Disclosure Information